FGA146
FGA146 is a dual, selective inhibitor for Mpro and human Cathepsin L, with Kis of 2.19 μM, 0.96 μM and 0.87 μM, for Mal-Mpro, pET21-Mpro and Cathepsin L, respectively. FGA146 reveals an antiviral activity against SARS-CoV-2.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Fòrmula: C24H31N5O6
- Peso molecular:485.53
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Ver todos los productos específicos de isoformas Cathepsin
More
Actividad biológica
Descripciòn
IC50 & Target
[1]|
cathepsin L 0.87 μM (Ki) |
pET21-Mpro 0.96 μM (Ki) |
Mal-Mpro 2.19 μM (Ki) |
In Vitro
FGA146 reveals antiviral activity against SARS-CoV-2 with EC50 of 0.9 μM with low cytotoxicity[1].
FGA146 (25-100 μM) binds covalently to Mpro and decreases its thermal stability[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Huh-7-ACE2
-
Concentration:0-100 μM
-
Incubation Time:24 h
-
Result:Exhibited a CC50 of over 100 μM.
Chemical Information
-
Peso molecular 485.53
-
Fòrmula C24H31N5O6
-
SMILES
O=C(N[C@@H](C[C@@H]1CCNC1=O)/C=C/[N+]([O-])=O)[C@H](CC(C)C)NC(C2=CC(C(OC)=CC=C3)=C3N2)=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocolo
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
FGA146 Related Classifications
HY-161245 Related Classifications
Powered by Bioz